PaMeLaInc. (“PaMeLa”) announces that it has been selected for the NQ Health Accelerator Program, an initiative focused on overseas market expansion jointly operated by AstraZeneca, Cambridge Consultants, and Medtech Actuator.

The program is a tailor-made global accelerator program that partners with Nakanoshima Qross to bring together promising life-science startups. Through the provision of customized startup support and overseas travel support programs, the initiative aims to foster startups that can thrive globally by leveraging the respective strengths of AstraZeneca, Cambridge Consultants, and Medtech Actuator, with a strong focus on international market expansion.

Leveraging this selection, PaMeLa will further accelerate its business development in global markets and continue working toward the broader societal implementation of its innovative medical technologies.

Reference Link: https://nq-gateway.jp/archives/365 (Only Japanese available)